Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $301
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Overweight and raises the price target from $232 to $301.